This is an aggregated industry headline. Read the full story at Drug Channels →
The Hidden Cost of 340B for Employers and Health Plans
By Adam J. Fein, Ph.D.For years, the controversy surrounding the 340B Drug Pricing Program has centered on hospitals, manufacturers, and contract pharmacies. But employers and health plans have become major participants in the program's economics-even though many don't realize it. The short video be
By Drug Channels
· Jul 8, 2026
· via Drug Channels
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
As Amgen's flagship PCSK9 cholesterol drug Repatha enjoys a bit of a renaissance on the back of impressive car…
The WeekFierceBiotech ↗
Contract research organization Icon announced a multi-year collaboration with Anthropic this week to bring Cla…
The WeekBriefing
A new analysis challenged a controversial federal-law provision that exempts certain orphan drugs from Medicar…